Eleni Efstathiou1, Mark Titus2, Sijin Wen3, Patricia Troncoso4, Anh Hoang2, Paul Corn2, Ina Prokhorova4, John Araujo5, Carl Dmuchowski6, Amal Melhem-Bertrandt6, Shiva Patil6, Christopher J Logothetis2. 1. Department of Genitourinary Medical Oncology, Stanford Alexander Tissue Derivatives Laboratory, David H. Koch Center for Applied Research of Genitourinary Cancers, Houston, TX, USA; Department of Clinical Therapeutics, University of Athens, Athens, Greece. Electronic address: eefstathiou@mdanderson.org. 2. Department of Genitourinary Medical Oncology, Stanford Alexander Tissue Derivatives Laboratory, David H. Koch Center for Applied Research of Genitourinary Cancers, Houston, TX, USA. 3. Department of Biostatistics, West Virginia University, Morgantown, WV, USA. 4. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Astellas Pharma, Inc., Northbrook, IL, USA.
Abstract
BACKGROUND: It is hypothesised that cotargeting the androgen receptor (AR) and paracrine androgen biosynthesis with enzalutamide and abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC) will dissipate adaptive feedback loops observed with either agent alone. OBJECTIVE: To assess the safety, efficacy, androgen signalling/metabolome, and drug-drug interactions (DDIs) of enzalutamide with abiraterone acetate in progressive bone mCRPC (bmCRPC). DESIGN, SETTING, AND PARTICIPANTS: This open-label, single-centre interventional study was conducted in bmCRPC patients. INTERVENTION: Enzalutamide 160mg and abiraterone acetate 1000mg once daily; prednisone 5mg twice daily. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Adverse events (AEs), prostate-specific antigen (PSA) response, progression-free survival (PFS), tumour biomarker/metabolite expression, and Cmin plasma concentrations were evaluated. RESULTS AND LIMITATIONS: Sixty patients were enrolled. Common AEs independent of grade/causality included fatigue (72%), hyperglycaemia (67%), alkaline phosphatase (ALP) elevation (53%), and hot flush (43%). Grade 3 AEs included hypertension (17%), alanine aminotransferase elevation (12%), ALP elevation (5%), and arthralgia (5%). No treatment-related grade 4 AEs or deaths were reported. Median treatment-discontinuation time was 312d (95% confidence interval [CI] 196.0-483.0). Maximal PSA decline ≥50% and ≥90% occurred in 46 (77%) and 29 (48%) patients, respectively. Median PFS was 251d (95% CI 147-337). At week 9, median tumour microenvironment androgens, precursors, and nuclear AR expression decreased (p<0.001). The baseline tumour AR C/N terminal ratio of ≥80% was associated with treatment benefit. At enzalutamide steady state, abiraterone acetate Cmin was ∼23% lower (range 14.05-200.5ng/ml) than when given alone. CONCLUSIONS: Enzalutamide combined with abiraterone acetate has a manageable safety profile, without a meaningful DDI. Both agents are pharmacodynamically active with no feedback. Efficacy findings do not support significant benefit of combined treatment for unselected bmCRPC. PATIENT SUMMARY: This is the first study combining enzalutamide plus abiraterone in bone metastatic castration-resistant prostate cancer. Results show that this combination is safe.
BACKGROUND: It is hypothesised that cotargeting the androgen receptor (AR) and paracrine androgen biosynthesis with enzalutamide and abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC) will dissipate adaptive feedback loops observed with either agent alone. OBJECTIVE: To assess the safety, efficacy, androgen signalling/metabolome, and drug-drug interactions (DDIs) of enzalutamide with abiraterone acetate in progressive bone mCRPC (bmCRPC). DESIGN, SETTING, AND PARTICIPANTS: This open-label, single-centre interventional study was conducted in bmCRPC patients. INTERVENTION: Enzalutamide 160mg and abiraterone acetate 1000mg once daily; prednisone 5mg twice daily. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Adverse events (AEs), prostate-specific antigen (PSA) response, progression-free survival (PFS), tumour biomarker/metabolite expression, and Cmin plasma concentrations were evaluated. RESULTS AND LIMITATIONS: Sixty patients were enrolled. Common AEs independent of grade/causality included fatigue (72%), hyperglycaemia (67%), alkaline phosphatase (ALP) elevation (53%), and hot flush (43%). Grade 3 AEs included hypertension (17%), alanine aminotransferase elevation (12%), ALP elevation (5%), and arthralgia (5%). No treatment-related grade 4 AEs or deaths were reported. Median treatment-discontinuation time was 312d (95% confidence interval [CI] 196.0-483.0). Maximal PSA decline ≥50% and ≥90% occurred in 46 (77%) and 29 (48%) patients, respectively. Median PFS was 251d (95% CI 147-337). At week 9, median tumour microenvironment androgens, precursors, and nuclear AR expression decreased (p<0.001). The baseline tumourAR C/N terminal ratio of ≥80% was associated with treatment benefit. At enzalutamide steady state, abiraterone acetate Cmin was ∼23% lower (range 14.05-200.5ng/ml) than when given alone. CONCLUSIONS:Enzalutamide combined with abiraterone acetate has a manageable safety profile, without a meaningful DDI. Both agents are pharmacodynamically active with no feedback. Efficacy findings do not support significant benefit of combined treatment for unselected bmCRPC. PATIENT SUMMARY: This is the first study combining enzalutamide plus abiraterone in bone metastatic castration-resistant prostate cancer. Results show that this combination is safe.
Authors: Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin Journal: Cancer Discov Date: 2013-06-28 Impact factor: 39.397
Authors: Howard I Scher; Ryon P Graf; Nicole A Schreiber; Brigit McLaughlin; David Lu; Jessica Louw; Daniel C Danila; Lyndsey Dugan; Ann Johnson; Glenn Heller; Martin Fleisher; Ryan Dittamore Journal: Eur Urol Date: 2016-12-12 Impact factor: 20.096
Authors: Howard I Scher; Tomasz M Beer; Celestia S Higano; Aseem Anand; Mary-Ellen Taplin; Eleni Efstathiou; Dana Rathkopf; Julia Shelkey; Evan Y Yu; Joshi Alumkal; David Hung; Mohammad Hirmand; Lynn Seely; Michael J Morris; Daniel C Danila; John Humm; Steve Larson; Martin Fleisher; Charles L Sawyers Journal: Lancet Date: 2010-04-14 Impact factor: 79.321
Authors: Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo Journal: N Engl J Med Date: 2014-09-03 Impact factor: 91.245
Authors: Nicholas D James; Johann S de Bono; Melissa R Spears; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Alastair W S Ritchie; Claire L Amos; Clare Gilson; Rob J Jones; David Matheson; Robin Millman; Gerhardt Attard; Simon Chowdhury; William R Cross; Silke Gillessen; Christopher C Parker; J Martin Russell; Dominik R Berthold; Chris Brawley; Fawzi Adab; San Aung; Alison J Birtle; Jo Bowen; Susannah Brock; Prabir Chakraborti; Catherine Ferguson; Joanna Gale; Emma Gray; Mohan Hingorani; Peter J Hoskin; Jason F Lester; Zafar I Malik; Fiona McKinna; Neil McPhail; Julian Money-Kyrle; Joe O'Sullivan; Omi Parikh; Andrew Protheroe; Angus Robinson; Narayanan N Srihari; Carys Thomas; John Wagstaff; James Wylie; Anjali Zarkar; Mahesh K B Parmar; Matthew R Sydes Journal: N Engl J Med Date: 2017-06-03 Impact factor: 91.245
Authors: Eleni Efstathiou; Mark Titus; Sijin Wen; Anh Hoang; Maria Karlou; Robynne Ashe; Shi Ming Tu; Ana Aparicio; Patricia Troncoso; James Mohler; Christopher J Logothetis Journal: Eur Urol Date: 2014-05-29 Impact factor: 20.096
Authors: Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi Journal: N Engl J Med Date: 2017-06-04 Impact factor: 91.245
Authors: Christopher P Vellano; Michael G White; Miles C Andrews; Manoj Chelvanambi; Russell G Witt; Joseph R Daniele; Mark Titus; Jennifer L McQuade; Fabio Conforti; Elizabeth M Burton; Matthew J Lastrapes; Gabriel Ologun; Alexandria P Cogdill; Golnaz Morad; Peter Prieto; Alexander J Lazar; Yanshuo Chu; Guangchun Han; M A Wadud Khan; Beth Helmink; Michael A Davies; Rodabe N Amaria; Jeffrey J Kovacs; Scott E Woodman; Sapna Patel; Patrick Hwu; Michael Peoples; Jeffrey E Lee; Zachary A Cooper; Haifeng Zhu; Guang Gao; Hiya Banerjee; Mike Lau; Jeffrey E Gershenwald; Anthony Lucci; Emily Z Keung; Merrick I Ross; Laura Pala; Eleonora Pagan; Rossana Lazcano Segura; Qian Liu; Mikayla S Borthwick; Eric Lau; Melinda S Yates; Shannon N Westin; Khalida Wani; Michael T Tetzlaff; Lauren E Haydu; Mikhila Mahendra; XiaoYan Ma; Christopher Logothetis; Zachary Kulstad; Sarah Johnson; Courtney W Hudgens; Ningping Feng; Lorenzo Federico; Georgina V Long; P Andrew Futreal; Swathi Arur; Hussein A Tawbi; Amy E Moran; Linghua Wang; Timothy P Heffernan; Joseph R Marszalek; Jennifer A Wargo Journal: Nature Date: 2022-06-15 Impact factor: 69.504
Authors: Riikka Huhtaniemi; Petra Sipilä; Arttu Junnila; Riikka Oksala; Matias Knuuttila; Arfa Mehmood; Eija Aho; Teemu D Laajala; Tero Aittokallio; Asta Laiho; Laura Elo; Claes Ohlsson; Malin Hagberg Thulin; Pekka Kallio; Sari Mäkelä; Mika V J Mustonen; Matti Poutanen Journal: iScience Date: 2022-04-25
Authors: Salah-Eddine Lamhamedi-Cherradi; Mayinuer Maitituoheti; Brian A Menegaz; Sandhya Krishnan; Amelia M Vetter; Pamela Camacho; Chia-Chin Wu; Hannah C Beird; Robert W Porter; Davis R Ingram; Vandhana Ramamoorthy; Sana Mohiuddin; David McCall; Danh D Truong; Branko Cuglievan; P Andrew Futreal; Alejandra Ruiz Velasco; Nazanin Esmaeili Anvar; Budi Utama; Mark Titus; Alexander J Lazar; Wei-Lien Wang; Cristian Rodriguez-Aguayo; Ravin Ratan; J Andrew Livingston; Kunal Rai; A Robert MacLeod; Najat C Daw; Andrea Hayes-Jordan; Joseph A Ludwig Journal: Nat Commun Date: 2022-06-01 Impact factor: 17.694
Authors: Nathalie Bock; Thomas Kryza; Ali Shokoohmand; Joan Röhl; Akhilandeshwari Ravichandran; Marie-Luise Wille; Colleen C Nelson; Dietmar W Hutmacher; Judith A Clements Journal: Sci Adv Date: 2021-06-30 Impact factor: 14.136
Authors: Fred Saad; Eleni Efstathiou; Gerhardt Attard; Thomas W Flaig; Fabio Franke; Oscar B Goodman; Stéphane Oudard; Thomas Steuber; Hiroyoshi Suzuki; Daphne Wu; Kesav Yeruva; Peter De Porre; Sabine Brookman-May; Susan Li; Jinhui Li; Shibu Thomas; Katherine B Bevans; Suneel D Mundle; Sharon A McCarthy; Dana E Rathkopf Journal: Lancet Oncol Date: 2021-09-30 Impact factor: 54.433